marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2022-Q3
added 11-14-2022
CASI Pharmaceuticals Balance Sheet 2011-2024 | CASI
Annual Balance Sheet CASI Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-36.5 M | -55.8 M | -51.4 M | -82.7 M | -42 M | -25.6 M | -3.67 M | -9.28 M | -15.1 M | -7.95 M | -1.08 M |
Long Term Debt |
1.1 M | - | - | - | 1.5 M | 1.49 M | 1.46 M | 1.39 M | - | - | - |
Long Term Debt Current |
1.06 M | 939 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 38.2 M | 21.7 M | 73.6 K | 1.5 M | 5.61 M | 10.9 M | 10.8 M | - | - | - |
Total Current Liabilities |
13.2 M | 7.98 M | 7.95 M | 3.87 M | 5.06 M | 1.32 M | 1.05 M | 919 K | 565 K | 743 K | 704 K |
Total Liabilities |
30.3 M | 46.2 M | 29.6 M | 3.95 M | 6.56 M | 6.93 M | 11.9 M | 11.7 M | 565 K | 743 K | 704 K |
Deferred Revenue |
- | 2.35 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-606 M | -571 M | -524 M | -479 M | -453 M | -442 M | -432 M | -425 M | -399 M | -393 M | -379 M |
Total Assets |
138 M | 128 M | 103 M | 113 M | 45.1 M | 27.7 M | 5.83 M | 11.3 M | 15.5 M | 8.98 M | 3.24 M |
Cash and Cash Equivalents |
38.7 M | 57.1 M | 53.6 M | 84.2 M | 43.5 M | 27.1 M | 5.13 M | 10.7 M | 15.1 M | 8.05 M | 1.08 M |
Book Value |
108 M | 81.5 M | 73 M | 109 M | 38.5 M | 20.8 M | -6.09 M | -422 K | 14.9 M | 8.24 M | 2.53 M |
Total Shareholders Equity |
84.5 M | 81.5 M | 73 M | 109 M | 38.5 M | 20.8 M | -6.09 M | -422 K | 14.9 M | 8.24 M | 2.53 M |
All numbers in USD currency
Quarterly Balance Sheet CASI Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 634 K | 858 K | 894 K | 1.1 M | 1.43 M | 1.63 M | 769 K | 965 K | 181 K | 259 K | 704 K | 1.02 M | 1.29 M | 1.63 M | 1.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 44.7 M | 29.3 M | 30.8 M | 30.3 M | 26.8 M | 27 M | 25.9 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 8.97 M | 8.97 M | 8.97 M | 8.97 M | 3.95 M | 3.95 M | 3.95 M | 3.95 M | 6.56 M | 6.56 M | 6.56 M | 6.56 M | 6.93 M | 6.93 M | 6.93 M | 6.93 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 565 K | 565 K | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -625 M | -621 M | -614 M | -606 M | -600 M | -590 M | -584 M | -571 M | -571 M | -571 M | -571 M | -524 M | -524 M | -524 M | -524 M | -479 M | -479 M | -479 M | -479 M | -453 M | -453 M | -453 M | -453 M | -442 M | -442 M | -442 M | -442 M | -432 M | -432 M | -432 M | -432 M | -425 M | -425 M | -425 M | -425 M | -399 M | -399 M | -399 M | -399 M | -393 M | -393 M | -393 M | -393 M | -379 M | -379 M | -379 M | -379 M |
Total Assets |
- | 128 M | 119 M | 130 M | 138 M | 136 M | 145 M | 148 M | 128 M | 128 M | 128 M | 128 M | 103 M | 103 M | 103 M | 103 M | 113 M | 113 M | 113 M | 113 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 5.83 M | 5.83 M | 5.83 M | 5.83 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 3.24 M | 3.24 M | 3.24 M | 3.24 M |
Cash and Cash Equivalents |
- | 26.7 M | 18.9 M | 29.3 M | 38.7 M | 53.1 M | 60.4 M | 68.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 53.6 M | 53.6 M | 53.6 M | 53.6 M | 84.2 M | 84.2 M | 84.2 M | 84.2 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 5.13 M | 5.13 M | 5.13 M | 5.13 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 8.05 M | 8.05 M | 8.05 M | 8.05 M | 1.08 M | 1.08 M | 1.08 M | 1.08 M |
Book Value |
- | 83.2 M | 89.6 M | 98.7 M | 108 M | 110 M | 117 M | 122 M | 104 M | 104 M | 104 M | 104 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 109 M | 109 M | 109 M | 109 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | -6.09 M | -6.09 M | -6.09 M | -6.09 M | -422 K | -422 K | -422 K | -422 K | 14.9 M | 14.9 M | 15.5 M | 15.5 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 3.24 M | 3.24 M | 3.24 M | 3.24 M |
Total Shareholders Equity |
- | 61.7 M | 66.9 M | 75 M | 84.5 M | 86.6 M | 94.8 M | 100 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 73 M | 73 M | 73 M | 73 M | 109 M | 109 M | 109 M | 109 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | -6.09 M | -6.09 M | -6.09 M | -6.09 M | -422 K | -422 K | -422 K | -422 K | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 8.24 M | 8.24 M | 8.24 M | 8.24 M | 2.53 M | 2.53 M | 2.53 M | 2.53 M |
All numbers in USD currency